Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer

Conditions

• Cervical Cancer

Eligibility Criteria

Sex

FEMALE

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• TIVDAK — DRUG
  2 mg/kg once every 3 weeks (Q3W)

Study Details

TIVDAK is used for the treatment of cervical cancer that has come back after chemotherapy. Chemotherapy is a treatment that uses medicines to stop the growth of cancer cells. This is done either by killing the cells or by stopping them from growing. The purpose of this study is to learn about possible side effects of TIVDAK, specially to any side effect that is related to the eye. A side effect is anything a medicine does to your body that is not part of how the medicine treats disease. * This study is seeking for participants who: Are willing to take all the required eye tests * Have not received TIVDAK before * Do not have any active eye issues. Participants will receive TIVDAK once every 3 weeks as an infusion that will be injected into the vein. Participants will visit an eye care provider at 3 stages: * before starting the treatment, * before each of the first 9 infusions * then monthly for 3 months after they stop taking TIVDAK. Treatment with TIVDAK will continue until it is not working anymore against the participant's cancer.

Key Dates

Start date

May 7, 2025

Status verified

Apr 2026

Primary completion

Dec 13, 2028

Completion

Dec 13, 2028

Study Design

Enrollment

100 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

OTHER

Arms

• Experimental: Tisotumab vedotin
  Participants will receive tisotumab vedotin by IV infusion.

Primary Outcome Measure

Type, incidence and severity of ocular adverse events (AEs) [ Time Frame: 90 days after the last dose of tisotumab vedotin ]

Central Contacts

• Pfizer CT.gov Call Center
  1-800-718-1021
  [email protected]

Locations (92)

Find similar trials in Phoenix, AZ

Related Studies

• Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
  Recruiting · Northwestern University · Chicago, Illinois
• Study of NEO-201 in Solid Tumors Expansion Cohorts
  PHASE1/PHASE2 · Recruiting · Precision Biologics, Inc · Bethesda, Maryland
• FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
  Recruiting · University Health Network, Toronto · Houston, Texas
• Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
  PHASE1 · Recruiting · M.D. Anderson Cancer Center · Houston, Texas